INSMED Inc — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2021-11-01

Reporting Person: Schaeffer Orlov S Nicole (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	61000	$12.44	Acquired	112514	Direct
2021-11-01	Common Stock	S	60660	$30.28	Disposed	51854	Direct
2021-11-01	Common Stock	S	340	$31.08	Disposed	51514	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (right to buy)	$12.44	M	36000	Disposed	2023-05-23	Common Stock (36000)	Direct
2021-11-01	Stock Option (right to buy)	$12.44	M	25000	Disposed	2023-05-23	Common Stock (25000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Includes 722 shares acquired through the Company's 2018 Employee Stock Purchase Plan.

F3: This is the weighted average sales price representing 60,660 shares sold at prices ranging from $30.00 to $30.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F4: This is the weighted average sales price representing 340 shares sold at prices ranging from $31.00 to $31.14 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

F5: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

F6: These options vested and became exercisable with respect to 12,500 shares upon receipt of the first written acceptance of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA); and with respect to the remaining 12,500 shares upon receipt of the first written approval of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA).